Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw some unusual options trading on Wednesday. Stock traders purchased 1,002 put options on the company. This represents an increase of 1,791% compared to the typical daily volume of 53 put options.

Maravai LifeSciences Price Performance

Shares of NASDAQ MRVI opened at $3.25 on Friday. Maravai LifeSciences has a 12 month low of $1.66 and a 12 month high of $6.21. The company has a current ratio of 5.29, a quick ratio of 4.49 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $829.92 million, a price-to-earnings ratio of -3.87 and a beta of 0.34. The business has a 50-day moving average of $3.03 and a 200-day moving average of $2.58.

Maravai LifeSciences (NASDAQ:MRVI) last announced its earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Maravai LifeSciences had a negative net margin of 62.88% and a negative return on equity of 22.42%. The company had revenue of $41.63 million during the quarter, compared to analysts’ expectations of $49.02 million. Sell-side analysts expect that Maravai LifeSciences will post -0.24 earnings per share for the current fiscal year.

Insider Transactions at Maravai LifeSciences

In related news, CEO Bernd Brust acquired 93,358 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were acquired at an average price of $3.21 per share, with a total value of $299,679.18. Following the acquisition, the chief executive officer owned 250,559 shares of the company’s stock, valued at approximately $804,294.39. This trade represents a 59.39% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 2.11% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Several hedge funds have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas purchased a new stake in Maravai LifeSciences in the first quarter worth approximately $37,000. Royce & Associates LP lifted its holdings in Maravai LifeSciences by 38.5% in the 1st quarter. Royce & Associates LP now owns 1,328,444 shares of the company’s stock worth $2,936,000 after buying an additional 369,559 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Maravai LifeSciences by 56.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 47,031 shares of the company’s stock worth $104,000 after acquiring an additional 16,914 shares during the period. XTX Topco Ltd increased its position in shares of Maravai LifeSciences by 160.4% during the first quarter. XTX Topco Ltd now owns 99,458 shares of the company’s stock valued at $220,000 after buying an additional 61,270 shares during the period. Finally, Monaco Asset Management SAM raised its position in shares of Maravai LifeSciences by 186.9% in the 1st quarter. Monaco Asset Management SAM now owns 835,865 shares of the company’s stock worth $1,847,000 after acquiring an additional 544,501 shares in the last quarter. Institutional investors own 50.25% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Tuesday, October 14th. Royal Bank Of Canada reduced their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating for the company in a research note on Tuesday, August 12th. Three research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Maravai LifeSciences presently has a consensus rating of “Hold” and a consensus price target of $5.22.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.